Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for CLL
Roche announced the EU Committee for Medicinal Products for Human Use has adopted a positive opinion for Venclyxto® (venetoclax) in combination with MabThera® (rituximab) for the treatment of people with chronic lymphocytic leukaemia who have received at least one prior therapy. September 21, 2018